The biotechnology segment of the overall biopharma industry has existed for only about 40–
45 years, as a driver of new product development. This driving force was initiated with the …

It costs about $1.2 billion to bring a single new drug to market in the US today. With a
combination of high late-stage failure rates and the high cost of drug trials, the number of …

Highlights•Biotech companies contributed to more than 2/3 of all drugs approved to
date.•The number of biotechs with approval is at a level not seen since the 1980s.•The …

There is no good measure of R&D productivity in the pharmaceutical and biotechnology
industry because of the long maturation time needed to bring drugs to the market. The R&D …

Although the biotech sector is conventionally thought to focus specifically on biologic drugs,
its track record of approvals for small-molecule drugs in'priority review'designations nearly …

Biologics have replaced small molecules as the dominant focus of big pharma's pipeline,
and a new analysis from the Tufts Center for the Study of Drug Development (Boston) has …

Some 160 biopharmaceuticals have now gained medical approval and several hundred are
in the pipeline. Most are protein-based, although two nucleic acid-based products are now …

This book and CD-ROM contain an extensive discussion of product development in the
pharmaceutical and biotechnology industries from discovery, to product launch, and through …

Over the past three decades, the biotechnology industry has emerged as a vital and
dynamic source of new technologies for the pharmaceutical and agricultural chemical …

Biopharmaceutical benchmarks 2006 | Nature Biotechnology Skip to main content Thank you
for visiting nature.com. You are using a browser version with limited support for CSS. To obtain …